SYNVIVIA
Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia creates engineered organisms that can be controlled with small molecules.
SYNVIVIA
Social Links:
Industry:
Biopharma Biotechnology Clinical Trials Life Science
Founded:
2016-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.synvivia.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
375.91 K USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Content Delivery Network LetsEncrypt SSL By Default HSTS Google Google Cloud Google Apps For Business
Similar Organizations
4M Therapeutics Inc.
4MTx is developing small molecules to treat neuropsychiatric disorders by enhancing neuroplasticity and reducing neuro-inflammation.
PhantaField
We invented the Iron man glasses
Principia Biopharma
Principia Biopharma is dedicated to bringing oral therapies to patients with significant unmet medical needs in immunology & oncology.
Prometrika
Prometrika is a clinical research organization that also provides data management, biostatistics, medical writing, and pharmacovigilance.
Trialize
Automating clinical trials with AI and RPA
Current Employees Featured
Founder
Investors List
California Innovation Fund
California Innovation Fund investment in Venture Round - Synvivia
Creative Ventures
Creative Ventures investment in Venture Round - Synvivia
National Science Foundation
National Science Foundation investment in Grant - Synvivia
For Good Ventures
For Good Ventures investment in Convertible Note - Synvivia
Y Combinator
Y Combinator investment in Seed Round - Synvivia
Newest Events participated
Official Site Inspections
http://www.synvivia.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Synvivia"
Syndivia – Making a difference in ADC with GeminiMab™ and …
At Syndivia, we are dedicated to advancing treatment options for cancer patients through our innovative GeminiMab™ Technology. This platform enables the creation of site-specific …See details»
About - Syndivia
©[YEAR] Syndivia, 8 Allée Gaspard Monge, ISIS, Strasbourg, Grand Est, 67083, France [email protected] [email protected]See details»
Synvivia - Crunchbase Company Profile & Funding
Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia …See details»
Syndivia - Crunchbase Company Profile & Funding
Organization. Syndivia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Syndivia is a biotechnology company based in …See details»
News - Syndivia
Nov 16, 2023 News & Press Archive. STRASBOURG, France, March 10, 2020 – Syndivia, a research-driven biotechnology company focused on the development of new therapeutic …See details»
SYNDIVIA Trademark of Syndivia - Registration Number 6104315
Chemical products in the nature of chemicals for use in industry and science. Pharmaceutical products for the prevention and treatment of cancer, inflammation, and genetic diseases. …See details»
Sasha Koniev - Syndivia - LinkedIn
Founder and CEO of Syndivia, a biotechnology company committed to delivering the best… · Expérience : Syndivia · Formation : HEC Paris · Lieu : Strasbourg · 500 relations ou plus sur …See details»
著名诺贝尔奖获得者Jean-Marie Lehn被任命为Syndivia科学咨询委 …
Nov 16, 2023 Syndivia的首席执行官Sasha Koniev对这项任命表示兴奋，并表示：“我们很荣幸欢迎Jean-Marie Lehn教授来到Syndivia。 他对超分子化学领域的杰出贡献，加上他对科学创新 …See details»
Syndivia and TVM Capital Life Science Announce Creation of …
Jan 13, 2022 Jean-Yves Bonnefoy, President of Syndivia and Member of the Board of Auricula Biosciences, commented: “We are very excited to team up with TVM Capital Life Science and …See details»
Next generation drug conjugates for cancer treatment | Syndivia ...
Periodic Reporting for period 1 - Syndivia (Next generation drug conjugates for cancer treatment) Reporting period: 2016-07-01 to 2016-11-30 Summary of the context and overall objectives of …See details»
Syndivia Receives €2m Deeptech Financing From Bpifrance to …
Mar 10, 2020 https://www.syndivia.com. Media Contact. Syndivia Sasha Koniev, CEO Phone: 00 33 3 67 10 42 20 Email: [email protected] Related Files. PR DEEPTECH …See details»
Vision - Syndivia
At Syndivia, we are dedicated to advancing treatment options for cancer patients through our innovative GeminiMab™ Technology. This platform enables the creation of site-specific …See details»
Syndivia Raises €1M Investment to Advance Its Tumour …
Dec 10, 2019 Syndivia is a company that is developing a platform for the targeted therapy of solid cancers by leveraging a unique microenvironment and anatomical hallmarks of these …See details»
Renowned Nobel Laureate Jean-Marie Lehn Appointed Chairman …
Nov 16, 2023 Syndivia, a leading biotechnology company at the forefront of innovative DAR1 ADCs (antibody-drug conjugates with a drug-to-antibody ratio of 1), is excited to announce the …See details»
OGD2 Pharma and Syndivia launch collaboration to develop an
NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting...See details»
Pipeline - Syndivia
2017: Out-licensing agreement established with Inatherys, limited to one target (CD71). The ADC is currently undergoing phase I/IIa clinical trial (NCT03957915). 2022: Auricula Biosciences co …See details»
Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of …
Jan 28, 2020 For more information, visit https://www.syndivia.com. Media Contact. Syndivia Sasha Koniev – CEO Phone: 00 33 3 67 10 42 20 Email: [email protected] Related Files. PR …See details»
SDV-2102 - Drug Targets, Indications, Patents - Synapse - Patsnap
Mar 7, 2025 SDV-2102, Initially developed by Syndivia SAS, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms,Urogenital Diseases, Active Indication: …See details»
EGFR(Syndivia) - Drug Targets, Indications, Patents - Synapse
2 days ago BACKGROUND The aim of this study was to validate the antitumor function of EGFR-chimeric antigen T-cells (CART) targeted to FaDu cells, a hypopharyngeal squamous …See details»
Publication in Chemical Society Reviews — Syndivia
Syndivia. May 22, 2015. Publication in Chemical Society Reviews. Syndivia. May 22, 2015. An advanced review article outlining recent developments in the field of bioconjugation has been …See details»